Arrhythmia Continuous Detection Device: Comprehensive Global Procurement & Clinical Integration Guide

Clinical studies validate that multi-wavelength PPG (combining Green, Red, and Infrared spectrums) achieves over 95% sensitivity and specificity for screening Atrial Fibrillation during resting and low-motion states. To satisfy rigorous clinical diagnostic criteria, the CardioWatch 287 allows immediate single-lead ECG rhythm strip capture, enabling cardiologists to confirm rhythm irregularities flagged by the continuous PPG screening algorithm.

Hospital ward deployment requires medical-grade device certification. In the European Union, devices must be certified under the strict EU Medical Device Regulation (CE-MDR Class IIa/IIb). In the United States, FDA 510(k) clearance is mandatory for clinical vital-sign claims. Consumer wearables lacking these certifications cannot be lawfully used for diagnostic escalation or formal EMR documentation.

Yes. Unlike proprietary consumer devices that lock physiological data behind black-box summary scores, Corsano provides full, IP-free access to raw 128 Hz accelerometer, multi-wavelength PPG, single-lead ECG, skin temperature, and Galvanic Skin Response (GSR) signals via cloud APIs and mobile SDKs. This transparency allows pharmaceutical companies and research institutions to build custom digital biomarkers and machine learning algorithms.

Paroxysmal AFib and post-surgical arrhythmias often develop silently following patient discharge. Continuous remote monitoring alerts care management teams to subclinical heart rate variability (HRV) degradation and rhythm disturbances days before acute symptoms emerge. Early pharmaceutical adjustment or intervention prevents emergency room visits and reduces 30-day readmissions by up to 35%.

The CardioWatch 287 features an optimized low-power architecture that supports continuous multi-day monitoring on a single charge. Its lightweight, skin-friendly watch form factor achieves compliance rates exceeding 90% in long-term clinical trials—far outperforming invasive chest straps, wired Holter monitors, or irritating adhesive patch sensors.

Data transmitted between the CardioWatch bracelet, gateway application, and cloud infrastructure is protected using end-to-end AES-256 encryption. The Corsano cloud platform is fully compliant with EU GDPR and US HIPAA standards, incorporating role-based access control (RBAC), secure token authentication, and rigorous data segregation to safeguard Protected Health Information (PHI).

Corsano provides documented RESTful APIs and mobile SDKs (iOS/Android) supporting HL7 and FHIR data standards. Vital signs, Early Warning Scores (EWS), and validated arrhythmia events can be ingested directly into hospital EMR systems (such as Epic or Cerner) or third-party central nursing telemetry dashboards without altering established clinical workflows.